dc.contributor.author | Cronin, Paula | |
dc.contributor.author | Kirkbride, Brent | |
dc.contributor.author | Bang, Albert | |
dc.contributor.author | Parkinson, Bonny | |
dc.contributor.author | Smith, David | |
dc.contributor.author | Haywood, Philip | |
dc.date.accessioned | 2018-10-16T06:27:57Z | |
dc.date.available | 2018-10-16T06:27:57Z | |
dc.date.issued | 2017 | |
dc.identifier.issn | 1743-7555 | |
dc.identifier.doi | 10.1111/ajco.12582 | |
dc.identifier.uri | http://hdl.handle.net/10072/100214 | |
dc.description.abstract | Aim: Prostate cancer (PCa) is the most commonly diagnosed cancer in Australian males. There are limited
data on the long-term health system costs associated with PCa. The aim of this study is to estimate long-term
health care costs of PCa.
Methods: We estimated the health system costs for a cohort of 1873 males diagnosed with PCa between 2000
and 2002, using linked medical, pharmaceutical and hospital data. Treatment was defined by an initial phase,
measuring health care costs up to 6 months following diagnosis and a continuing phase (including metastatic
treatment), measuring treatments to 9.5 years. Nonparametric models were used to calculate average health
care costs by PCa risk groups at diagnosis (low to metastatic) and treatment pathways.
Results: Health system costs increased with increasing PCa risk category, from $16 923 (low risk) to $39 101
(metastatic risk group). For men with initial localized risk, costs were $8 454 for the active surveillance treatment
pathway, $9621 for external beam radiation therapy/brachytherapy, $19 210 for androgen deprivation
therapy, $20 636 for radical prostatectomy, $21 161 for radical prostatectomy + external beam radiation
therapy/brachytherapy, $21 388 for any of the treatments previously listed + androgen deprivation therapy,
with an additional cost of $55 370 if metastatic treatment was undertaken.
Conclusions: Treatment costs are highest during two phases over the natural cycle of the disease, the initial
diagnosis phase and the metastatic treatment phase. Both the initial phase costs and low-risk category costs are
driven largely by the rates of radical prostatectomy. Our study provides comprehensive long-term estimates
of PCa costs. | |
dc.description.peerreviewed | Yes | |
dc.language | English | |
dc.publisher | Wiley-Blackwell Publishing | |
dc.relation.ispartofpagefrom | 1 | |
dc.relation.ispartofpageto | 12 | |
dc.relation.ispartofjournal | Asia-Pacific Journal of Clinical Oncology | |
dc.subject.fieldofresearch | Oncology and carcinogenesis | |
dc.subject.fieldofresearch | Oncology and carcinogenesis not elsewhere classified | |
dc.subject.fieldofresearchcode | 3211 | |
dc.subject.fieldofresearchcode | 321199 | |
dc.title | Long-term health care costs for patients with prostate cancer: A population-wide longitudinal study in New South Wales, Australia | |
dc.type | Journal article | |
dc.type.description | C1 - Articles | |
dc.type.code | C - Journal Articles | |
gro.description.notepublic | This publication has been entered into Griffith Research Online as an Advanced Online Version. | |
gro.hasfulltext | No Full Text | |
gro.griffith.author | Smith, David | |